إعلان
إعلان

PVLA

PVLA logo

Palvella Therapeutics, Inc. Common Stock

92.39
USD
برعاية
-4.99
-5.13%
٠٩ يناير, ١٥:٥٩ UTC -5
مغلق
exchange

بعد الإغلاق

93.40

+1.01
+1.10%

تقارير أرباح PVLA

النسبة الإيجابية المفاجئة

PVLA تفوق 22 من 36 آخر التقديرات.

61%

التقرير التالي

بيانات التقرير القادم
٣٠ مارس ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.91
التغير الضمني من Q3 25 (Revenue/ EPS)
--
/
-11.65%
التغير الضمني من Q4 24 (Revenue/ EPS)
--
/
-66.54%

Palvella Therapeutics, Inc. Common Stock earnings per share and revenue

On ١١ نوفمبر ٢٠٢٥, PVLA reported earnings of -1.03 USD per share (EPS) for Q3 25, missing the estimate of -0.85 USD, resulting in a -20.45% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -3.04% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 17 المحللين forecast an EPS of -0.91 USD, with revenue projected to reach -- USD, implying an نقصان of -11.65% EPS, and زيادة of 0.00% in Revenue from the last quarter.
الأسئلة الشائعة
For Q3 2025, Palvella Therapeutics, Inc. Common Stock reported EPS of -$1.03, missing estimates by -20.45%, and revenue of $0.00, 0% as expectations.
The stock price moved down -3.04%, changed from $80.29 before the earnings release to $77.85 the day after.
The next earning report is scheduled for ٣٠ مارس ٢٠٢٦.
Based on 17 المحللين, Palvella Therapeutics, Inc. Common Stock is expected to report EPS of -$0.91 and revenue of -- for Q4 2025.
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان